{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [],
  "article_type": "review",
  "arxiv": null,
  "author_total": 0,
  "authors": [],
  "bibtex": "https://research.draconitic.com/paper/ckyxhzgyvpks9.bib",
  "cited_by": 0,
  "doi": null,
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/books/NBK625385",
  "id": "ckyxhzgyvpks9",
  "issns": [],
  "landing_url": "https://europepmc.org/article/MED/42899960",
  "language": "eng",
  "licence": "unknown",
  "licence_label": "Licence not stated",
  "licence_source": "unknown",
  "licence_url": null,
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": "42899960",
  "published": "2026-09-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/ckyxhzgyvpks9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "MED:42899960",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42899960"
    }
  ],
  "subjects": [],
  "title": "Inebilizumab (Uplizna): Indication: As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive: Reimbursement Recommendation",
  "title_text": "Inebilizumab (Uplizna): Indication: As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive: Reimbursement Recommendation",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:18Z",
  "url": "https://research.draconitic.com/paper/ckyxhzgyvpks9",
  "venue": null,
  "versions": []
}